3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Carcinoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Cancer Patients
1
Interventions
Bevacizumab
120
Fluorouracil
90
Cetuximab
84
Leucovorin
82
Oxaliplatin
80
pembrolizumab
70
Irinotecan
66
Nivolumab
46
Capecitabine
43
Specimen Handling
40
regorafenib
30
Folfox protocol
29
trifluridine tipiracil drug combination
28
Magnetic Resonance Spectroscopy
27
Biopsy
27
Panitumumab
26
HMPL-013
26
Standard of Care
25
IFL protocol
21
Gemcitabine
20
Blood Specimen Collection
19
tislelizumab
18
atezolizumab
18
Trifluridine
18
Cisplatin
18
balstilimab
16
Colonoscopy
16
Carboplatin
16
encorafenib
15
Paclitaxel
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
DEAE-Dextran
×
1 year
×
Clear all
NCT07403877
2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2
Not yet recruiting
114 enrolled